OPTN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	1.09M
Gjennomsnittsvolum	1.08M
Markedsverdi	113.78M
EPS	$0 ( 2024-03-07 )
Neste inntjeningsdato	( $-0.100 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.16
ATR14	$0.00300 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Krick Anthony J	Sell	2 345	Common Stock
2024-03-15	Marino Michael F Iii	Buy	3 816	Common Stock
2024-03-18	Marino Michael F Iii	Sell	15 059	Common Stock
2024-03-15	Mahmoud Ramy A	Buy	6 114	Common Stock
2024-03-18	Mahmoud Ramy A	Sell	19 198	Common Stock

INSIDER POWER
-24.21
Last 98 transactions
Buy: 6 923 187 \| Sell: 11 541 596

Volum Korrelasjon

Lang: 0.27 (neutral)

Kort: 0.94 (very strong)

Signal:(64.958) Expect same movement, but be aware

OptiNose Inc Korrelasjon

10 Mest positive korrelasjoner
FONR	0.899
EQIX	0.894
ULTA	0.872
GRPN	0.871
NUVL	0.868
CRSP	0.858
IPW	0.847
BIMI	0.846
KNSA	0.846
CTRN	0.84

10 Mest negative korrelasjoner
VMCAU	-0.869
LIVX	-0.854
LILA	-0.837
LILAK	-0.816
PCTTU	-0.809
GWAC	-0.804

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

OptiNose Inc Korrelasjon - Valuta/Råvare

-0.43
( neutral )

0.00
( neutral )

-0.55
( weak negative )

OptiNose Inc Økonomi

Annual	2023
Omsetning:	$70.99M
Bruttogevinst:	$61.95M (87.27 %)
EPS:	$-0.320

FY	2023
Omsetning:	$70.99M
Bruttogevinst:	$61.95M (87.27 %)
EPS:	$-0.320

FY	2022
Omsetning:	$76.28M
Bruttogevinst:	$67.01M (87.86 %)
EPS:	$-0.890

FY	2021
Omsetning:	$74.65M
Bruttogevinst:	$65.50M (87.74 %)
EPS:	$-1.450

Financial Reports:

No articles found.

OptiNose Inc

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Sanntidsoppdatering for OptiNose Inc [OPTN]

Upcoming Earnings Alert